Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [4266]

SABCS 2019: Partial breast irradiation may be as effective as whole breast irradiation in preventing recurrence in patients with early breast cancer

SABCS 2019: Partial breast irradiation may be as effective as whole breast irradiation in preventing recurrence in...

SABCS 2019: Adding tucatinib to drug combination extends survival for advanced HER2-positive breast cancer patients

SABCS 2019: Adding tucatinib to drug combination extends survival for advanced HER2-positive breast cancer patients

SABCS 2019: Neoadjuvant and adjuvant treatment with pembrolizumab improves pathologic complete response rates for patients with triple-negative breast cancer with lymph node involvement

SABCS 2019: Neoadjuvant and adjuvant treatment with pembrolizumab improves pathologic complete response rates for...

SABCS 2019: Updated APHINITY trial data show addition of pertuzumab to trastuzumab plus chemotherapy continues to yield clinical benefit in patients with operable HER2-positive early breast cancer

SABCS 2019: Updated APHINITY trial data show addition of pertuzumab to trastuzumab plus chemotherapy continues to...

SABCS 2019: Breast cancer preventive effects of anastrozole persist long after stopping treatment

SABCS 2019: Breast cancer preventive effects of anastrozole persist long after stopping treatment

SABCS 2019: Combining atezolizumab with neoadjuvant chemotherapy does not improve pathologic complete response rates for patients with triple-negative breast cancer

SABCS 2019: Combining atezolizumab with neoadjuvant chemotherapy does not improve pathologic complete response...

SABCS 2019: Addition of S-1 to post-operative endocrine therapy improves outcomes for patients with hormone receptor-positive, HER2-negative breast cancer

SABCS 2019: Addition of S-1 to post-operative endocrine therapy improves outcomes for patients with hormone...

SABCS 2019: New HER2 antibody-drug conjugate yielded promising clinical responses in breast cancer patients pretreated with T-DM1

SABCS 2019: New HER2 antibody-drug conjugate yielded promising clinical responses in breast cancer patients...

New prognostic markers for triple negative breast cancer confirmed

New prognostic markers for triple negative breast cancer confirmed

Immune checkpoint therapy for ER-positive breast cancers: A missed opportunity?

Immune checkpoint therapy for ER-positive breast cancers: A missed opportunity?

More from ecancer